BioWisdom Ltd has announced a three-year agreement with Johnson & Johnson Pharmaceutical Research & Development, Division of Janssen Pharmaceutica, NV (J&JPRD).
Under the terms of the agreement, J&JPRD will become the second partner for BioWisdom’s Safety Intelligence Program (SIP). The first partnership was formed with AstraZeneca. The financial details of the deal have not been disclosed.
The Safety Intelligence Program applies BioWisdom’s Sofia technology to deliver a specialist medical search system to support drug safety risk assessment at all stages of pharmaceutical R&D. Through the partnership, J&JPRD joins BioWisdom’s SIP board.
“We are delighted to have J&JPRD join our Safety Intelligence Program and look forward to working closely with safety assessment teams across the organization and affiliates” said Dr. Julie Barnes, Chief Scientific Officer of BioWisdom. “This second partnership is a testimony to the value that the pharmaceutical industry sees in our approach to drug safety and risk management.”
Dr Jack Reynolds, Chairman of the SIP Board said, “I am delighted to see the relationship between BioWisdom and J&JPRD established. I look forward to working with all partners on the SIP Board to advance the Safety Intelligence Program for the purpose of improving our understanding of many of the major recurring and potentially serious drug-induced adverse events.”